Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
History
Biology of the lysosome
Lysosomes and disease
Molecular pathogenesis
Disease progression
Presentation & progression
Disease management
Diagnosis & testing
Genetics
Summary of Product Characteristics
Gaucher
Fabry
MPS I
Pompe

 



 

History of the LSD Class[1]

Symptoms of some lysosomal storage disorders were first identified as early as the 1880s, and by the early 1900s many LSDs had been described and classified--although the lysosome itself was not discovered until 1955 by the Belgian biochemist Christian de Duve, who won the Nobel Prize for Medicine in 1974.

Many LSDs were identified before their biochemical and genetic basis was fully understood, so they received common names (for example, after the discovering physician). Later, an additional, more clinically descriptive name often came into use.

By the 1960s the role of lysosomes in cellular digestion and substrate management was well understood, and Pompe became the first disease formally recognized as a lysosomal storage disorder. By the 1970s the scientific community had recognized many more LSDs as such and had begun identifying and classifying the specific enzymatic problems.

References

1. Wilcox, WR. Lysosomal Storage Disorders: The Need for Better Pediatric Recognition and Comprehensive Care. Journal of Pediatrics; May 2004: S3-S14.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with CerezymeŽ

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with FabrazymeŽ significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease